EPHX3

Across TCGA pan-cancer cohorts, EPHX3 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated EPHX3 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher EPHX3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated EPHX3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC and LSCC are the cancer types where EPHX3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	All	0.938	0.699	.026	5	view →
LSCC	DFS	Median	II,III,IV	0.963	0.665	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

EPHX3–HNSC (OS)

Open the HNSC breakdown →